News

Number of news items returned: 81 to 100 records of 458

"AqMB Holdings ramping up water solutions software revenue ahead of potential trade sale from 2020 - MD"

05 April 2018

(9133 views)

  "AqMB Holdings ramping up water solutions software revenue ahead of potential trade sale from 2020 - MD   AqMB Holdings, a privately ...

"Supply Chain Inefficiencies In Emerging Markets: Is Blockchain The Answer?"

28 March 2018

(9485 views)

"Supply Chain Inefficiencies In Emerging Markets: Is Blockchain The Answer?   By Max Ward, CEO and Founder of OpenPort Emerging markets represent the ...

"Blockchain In Transit: OpenPort Paves New Road to Shipping Traceability and Transparency"

27 March 2018

(9863 views)

  Diamond-Michael Scott Digital Economy Journalist Specializing in Blockchain Technology| Fueling The Advancement of Freedom Through Technology "Blockchain In Transit: OpenPort Paves New ...

OpenPort

20 March 2018

(10272 views)

"Canoe Mining Enters Reverse-Takeover LOI with OpenPort, a Private Placement and Disposition of Assets   NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ...

Easter, Event, Introductions and News - Funding Strategies Connect March 2018

16 March 2018

(9740 views)

    Easter, Event, Introductions and News - Funding Strategies Connect March 2018   Dear Reader, Welcome to Funding Strategies Connect. We have seen a ...

JNCI publication involving CytImmune's CYT-21625

10 March 2018

(10271 views)

  "JNCI publication involving CytImmune's CYT-21625"   "Please find attached [via the link below] an article published in the most recent version of ...

AqMB introduces SupplierLink

08 March 2018

(10054 views)

  AqMB introduces SupplierLink   "Welcome to your virtual marketplace Process designers are busy people. Conferences and trade shows are expensive and the leads ...

"APRA to introduce first prudential standard aimed at tackling growing threat of cyber attacks"

07 March 2018

(9972 views)

"APRA to introduce first prudential standard aimed at tackling growing threat of cyber attacks"   Cyber Research has advised us of another ...

Support Management Solutions: Updates on Board and Development

27 February 2018

(10717 views)

    Support Management Solutions: Updates on Board and Development   "New Director Hugh Hamilton has been appointed to the Board. Hugh has experience in ...

Happy New Year - Funding Strategies Connect Jan 2018

06 February 2018

(8837 views)

    Happy New Year - Funding Strategies Connect Jan 2018   Dear Readers, Happy new year!   Flora Mok and myself were privileged to attend the ...

Squirrel Acquires London Based FCA Licensed Financial Service

05 February 2018

(8416 views)

    Squirrel Acquires London Based FCA Licensed Financial Service   "Squirrel Limited through its wholly owned UK based subsidiary, Squirrel Money Limited is ...

Mark's report on his recent Hong Kong visit

01 February 2018

(8456 views)

    Flora Mok and myself (pictured above) were privileged to attend the Asian Financial Forum, the Asia Private Equity Forum and ...

Dealer Trade Progress Report

25 January 2018

(6653 views)

    Dealer Trade has provided a progress report in regards to: Gumtree - CarRecord Partnership New Manufacturer - Suzuki QLD Dealer Trade UK Fairfax - ...

AqMB offers "PFD export to CAD software, smartPFD mode, plant rollback & simplified stream numbering"

25 January 2018

(7147 views)

    AqMB offers "PFD export to CAD software, smartPFD mode, plant rollback & simplified stream numbering"   Transition easily from BFD to PFD ...

"Support Management Solutions to raise capital for new medical software product"

23 January 2018

(8118 views)

    "Support Management Solutions to raise capital for new medical software product   Support Management Solutions to seek capital in 6-9 months to ...

2017 - its a wrap! Funding Strategies Connect December 2017

19 December 2017

(11102 views)

  2017 - its a wrap! Funding Strategies Connect December 2017     Dear Readers, 2017 - its a wrap! We have completed significant assignments for ...

Squirrel ranked 84th in the 2017 Deloitte Technology Fast 500 awards

18 December 2017

(11306 views)

  "Fresh off the back of Squirrel's recognition as one of the AFR's Fast Starters, I am pleased to announce we ...

Opmantek named 55th Australian Export Awards category winner

15 December 2017

(11040 views)

  Opmantek named  55th Australian Export Awards category winner     On the back of winning the 4th consecutive Queensland Premier's Export Award, Opmantek ...

BlueMount Capital Secures Major Debt Funding

07 December 2017

(10879 views)

    BlueMount Capital Secures Major Debt Funding   "In conjunction with BlueMount Capital’s Melbourne office, I am delighted to announce we have secured ...

"Walking over broken glass for sustainability"

06 December 2017

(10192 views)

    "Walking over broken glass for sustainability"   "Dr Ho’s team, along with industry partners Brisbane City Council and EnviroSand, are investigating mixtures ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625